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Abstract
Introduction: The objective of this study was to determine the expression levels of metallothionein (MT) and p53 protein,
recognized neoplastic transformation markers, in pancreatic serous cystadenomas (SCA) and adenomocarcinomas. 
Materials and Methods: Neoplastic pancreatic tissue was taken from 20 patients with diagnosed benign (SCA: 5 cases) or
malignant tumors (adenomocarcinomas: 15 cases) and control pancreatic tissue from healthy persons who had died in car
accidents. Sections were stained with hematoxylin-eosin. Immunohistochemical localization of MT and p53 protein was car-
ried out by LSAB2-HRP using specific antibodies against MT and p53. 
Results: Metallothionein expression was observed only in the epithelial cells of the neoplastic tissue of SCAs. MT expression
in the cystadenomas was weaker than in the healthy pancreatic tissue. No tissue was found with p53 protein expression. In
the adenomocarcinomas, positive staining for MT was observed in 67% and p53 was positive in the carcinoma cells.
Conclusion: The weak MT expression and lack of p53 protein expression in pancreatic SCAs confirms the lack of local inva-
sive potential of the neoplastic lesion. Increased expressions of MT and p53 were observed in the less differentiated tumors.
Thus the expression of MT may be a potential prognostic marker for tumors.
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INTRODUCTION
Metallothionein (MT) is a low-molecular-weight
metal-binding protein (Coyle et al. 2002; Kagi 1991)
which plays important roles in the detoxification of
heavy metals, homeostasis of essential metals, and scav-
enging of free radicals (Kagi 1991; Klassen et al. 1999;
Nath et al. 1988). Physiologically, MT level is low and
increases in response to the presence of heavy metals,
hormones (e.g. glucagon, glucocorticoids), as well as
cAMP, interleukins 1 and 6, interferon, and tumor
necrosis factor (Davis and Cousins 2000). Metallo-
thionein is present in many healthy tissues, such as
hepatic parenchymatous cells, kidneys, lungs, thymic
epithelial cells, erythrocytes, lymphocytes, and many
exo- and endocrine pancreatic cells (Cherian 1994;
Danielson et al. 1982; Tekada et al. 1997; Tomita 2000a;
Tomita 2000b). A number of studies have demonstrated
the presence or enhanced synthesis of MT in rapidly
proliferating normal cells, regenerating cells, and cancer
cells (Abdel-Mageed and Agrawal 1998). MT has been
considered a potential prognostic marker in invasive
ductal carcinomas of the breast (Schmid et al. 1993),
skin (Zelger et al. 1993), and pancreas (Ohshio et al.
1996). Irregular cell growth due to increased cell prolif-
eration or failure of cells to undergo apoptosis is recog-
nized as a major contributory factor to the malignant
process (Fan and Cherian 2002; Janssen et al. 2002;
Madej et al. 1999; Ohshio et al. 1996; Oyama et al. 1996;
Saga et al. 2002). However, the mechanism of tumor
MT expression is not fully understood. 
There are mechanisms in healthy and tumor cells
2009




, Published online: 2009.07.04 
296 M. S´liwin´ska-Mosson´ et al.: Metallothionein and p53 protein in SCA
allowing for interaction between MT and p53 protein
and for the growth cycle of dividing cells (Fan and
Cherian 2002). In vitro investigations have shown that
cell exposure to chelating metals induces changes in the
p53 gene’s three-dimensional structure, probably pre-
disposing to gene mutation (Cherian and Apostolova
2000). Irregularities in p53 gene are the most frequent
genetic disturbance in tumor cells. They are typical of
pancreatic adenocarcinoma (p53 gene mutation fre-
quency is estimated at 21–70%) and influence its biolo-
gy and prognosis. Previous studies showed that p53 pro-
tein expression in pancreatic tumors was related to poor
prognosis and worse histological grading of the tumors
(Pellegata et al. 1994).
Adenomas are very rare tumors, accounting for
0.5–1% of all pancreatic tumors, and serous cystadeno-
mas (SCAs) constitute 25% of them (Gerdes et al.
2003). SCAs, also known as glycogen-rich adenomas,
are rare benign tumors of the pancreas (Alrefaie et al.
2004; Compton 2000; Gerdes et al. 2003; Ishikawa et al
1998; Perez-Ordonez et al. 1996; Rabczynski et al. 2006;
Santos et al. 2002; Strobel et al. 2003). Increased SCA
morbidity occurs in patients over 60 years of age, with an
evident female preponderance (92%) (Compton 2000;
Ishikawa et al. 1998; Pellegata et al. 1994; Santos et al.
2002; Strobel et al. 2003). The histogenesis of pancreat-
ic SCA remains unknown and its detection is difficult at
each stage of the disease’s progression. An SCA is usu-
ally discovered incidentally or due to nonspecific
abdominal symptoms. Gastrointestinal symptoms, bil-
iary tract obstruction, and diabetes mellitus, when nor-
mal islets of Langerhans are destroyed by the tumor, are
the first signs observed in SCA patients. The majority of
SCAs are located in the pancreatic head. The rare
occurrence, unclear histogenesis, and differentiated
clinical symptoms of this disease result in even individ-
ual cases being subjected to a series of studies
(Compton 2000; Ishikawa et al. 1998; Santos et al. 2002;
Strobel et al. 2003).
Serous cystadenoma of the pancreas usually occurs
as a solitary and well-formed tumor with neoplasm. It
may sometimes also coexist with other pancreatic
tumors, such as adenocarcinomas or mucinus cystade-
noma (Alrefaie et al. 2004; del Vecchio et al. 2002;
Montag et al. 1990; Nitta et al. 2008; Posniak et al.
1991). The localization and role MT in SCA of the pan-
creas have not yet been reported in the literature. The
aim of this study was to identify immunohistochemically
the localization of MT and p53 protein and to determine
their expressions in pancreatic SCA.
MATERIALS AND METHODS
The study material was obtained from 20 patients
with diagnosed benign (serous cystadenoma: n=5) or
malignant tumors (adenomocarcinomas: n=15) hospi-
talized at the Department and Clinic of the Gastro-
enterological and General Surgery of Wroc³aw Medical
University between 1992 and 2001. The tumors of the
pancreas were classified histologically according to
World Health Organization criteria (Klöppel et al.
1996).
All the patients with SCA (five females 39–71 years
old, mean age: 55.2 years) were admitted due to persis-
tent abdominal pain and, in two cases, developing jaun-
dice. The diagnosis was made in all cases by means of
ultrasonography (USG), computed tomography, esoph-
agogastroduodenoscopy, and endoscopic retrograde
cholangiopancreatography. In case of diagnostic doubts,
magnetic resonance or magnetic resonance cholan-
giopancreatography and Doppler USG were made.
Cystic changes in the pancreas were found in all patients
during the preoperative examination. No family history
of changes and no characteristics of von Hippel Lindau
syndrome were detected in any case. Changes were
identified in two cases in the pancreas head, in one case
in the pancreas body, in one case at the border between
the body and tail, and in one case in the pancreas tail.
Resection was applied in all cases (Table 1).
The 15 cases of adenomocarcinoma consisted of 10
female and 5 male patients with a mean age of 50.6 years
(range: 29–77 years). Only 6 of the patients (40%)
underwent curative surgical resection and 3 (20%) had
palliative surgery. In the remaining cases, only tissue
sections of the pancreas were taken for histopathologi-
cal diagnosis. Changes were found in the pancreas head
in eleven cases and in the pancreas head and body in
Table 1. Characteristics of patients with serous cystadenoma of the pancreas (n=5)
No./ Location Type of surgery Post-surgery observation Coexisting diseases
/gender/ in the pancreas
/age
1/F/39 head pancreatodudenectomy 5 years chronic cholecystitis
Whipple procedure
2/F/46 head pancreatodudenectomy 6 years chronic cholecystitis
Whipple-Traverso procedure
3/F/64 body left-side resection of the pancreas 11 years none
4/F/56 body tail enucleation of the cyst 4 years chronic cholecystitis
5/F/71 tail left-side resection of the pancreas 3 years chronic mucosal gastritis
F – female.
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four. None of the patients had been treated with
chemotherapy and/or radiation therapy prior to pancre-
atic surgery. In one case the patient died after the oper-
ation, in eleven cases the time of post-operative obser-
vation was about three months, and in three cases about
nine months.
Control pancreatic tissue originated from healthy
persons who had died in car accidents. All tissue sec-
tions were routinely fixed in a phosphate-buffered 10%
formaldehyde solution and embedded in paraffin. Serial
4-µm-thick sections were stained with hematoxylin and
eosin and periodic acid-Schiff (PAS) and MT and p53
protein were localized immunohistochemically using the
method described earlier (Gerdes et al. 2003; Madej et
al. 1999; Pillai et al. 2003). 
This study was approved by the local institutional
committee (No. KB 257/2000) authorized to approve
research with human subjects and was funded by
Wroc³aw Medical University.
The serial tissue sections, deparaffinized and hydrat-
ed in an alcohol series, were incubated with a 3% hydro-
gen peroxide solution to block any intracellular peroxi-
dase activity. For p53 antigen retrieval, the sections
were boiled in citrate-buffered saline. Nonspecific
bonds were blocked using antibody diluent (DAKO,
Carpinteria, CA, USA; code: S0809). The tissue sec-
tions were subsequently incubated for 30 min at room
temperature with specific monoclonal antibodies
against MT (DAKO Carpinteria, CA, USA; code: E09)
and p53 (DAKO, code: N 1581). After washing in 0.05
M Tris-HCl (Bio-Rad Laboratories; Hercules, CA,
USA; code: 170-6435) with 0.1% Tween 20 (Sigma
Chemical, St. Louis, MO, USA; code: P1379) the anti-
body-hormone complexes were visualized using the
LSAB2-HRP test (DAKO, Carpinteria, CA, USA,
code: K0673). The peroxidase activity was located
against 3,3’-diaminbenzidine in an imidazole-HCL
buffer, pH 7.5. Then the sections were washed in dis-
tilled water, contrasted with hematoxylin (Chem
Mate™, DAKO Glostrup, Denmark; code: S2020),
closed in glycerin gel, and left to dry. A negative control
was performed for each tissue section by replacing the
primary antibody with an anti-rabbit IgG antibody
immunoglobulin control (Negative Control DAKO,
Carpinteria, CA, USA; code: X0903). 
The incubation times of the individual stages of the
test were matched experimentally under laboratory con-
ditions. The sections were stained with hematoxylin-
eosin and PAS stains. The stained tissue sections were
viewed under high power with an Olympus BX41 light
microscope (Olympus Optical Co. Ltd., Japan) inter-
faced to an Olympus DP70 digital camera (Olympus
Optical Co. Ltd., Japan) that digitized the microscopic
image.
Assessment of immunohistochemical staining
A semi-quantitative method was used to assess
histopathologically the intensity reaction of tissue spec-
imen staining: 0 no immunohistochemical reaction, +
weak reaction, ++ moderate reaction, +++ strong
reaction, and ++++ very strong reaction.
RESULTS
Tissue of normal pancreas
The exocrine and endocrine pancreatic cells were
normal. Clearly isolated islet cells showed a weak but
positive (+) dispersed expression of MT in the pancreas
on their whole surface. In all four control cases, no
immunohistochemical reaction (0) to MT was observed
in the pancreatic duct cells. A dispersed moderate (++)
reaction in all parts of the organ was found in few acinar
cells (Fig. 1). The immunohistochemical localization of
p53 was negative in normal pancreas (Fig. 2).
Tissue of pancreas with serous cystadenoma
The histopathological examination revealed features
characteristic of serous cystadenoma in all the SCA cases.
The tumor was composed of multilocular areas of various
diameters. A single layer of cuboidal epithelium lined the
cyst. Cells of similar size with a clear, slightly granular
cytoplasm with a single round or oval, slightly hyperchro-
matic nucleus were visible. Some single, fine nerve trunks
and vessels were visible in the connective septa. 
The immunohistochemical localization of p53 was
negative in all SCA cases (Figs. 4 and 6). In four cases,
MT expression was weak (+) and in one case moderate
(++). This is the first unusual case of a serous cystade-
noma that produces islet hormones, somatostatin, and
pancreatic polypeptide (Rabczynski et al. 2006). The
hormone expression was focal and limited to the lining
epithelium of a neoplastic cyst, similarly to the expres-
sion of MT (Fig. 5).
Tissue of pancreas with adenocarcinoma
Microscopically, an infiltrating ductal adenocarcino-
ma of the pancreas is an invasive malignant epithelial
neoplasm with ductal differentiation and without a pre-
dominant component of any of the other carcinoma
types. The tumor is composed of diverse (anaplastic)
cells with eosinophilic cytoplasm and a condensed
hyperchromatic nucleus with large conspicuous nucle-
oli. Many tumor cells contain unusually large nuclei with
unequally disposed chromatin. Less differentiated pan-
creatic adenomocarcinomas were detected in all the
pancreatic sections of the patients. 
MT immunostaining was diffusely or focally strong
positive (+++) in 10 of the cases (67%) of pancreatic
carcinoma (results described earlier) (Milnerowicz et al.
2006). In most cases both nuclear and cytoplasmic stain-
ing were observed (Fig. 7). The immunohistochemical
localization of p53 was positive in the carcinoma cells
(Fig. 8). 
298 M. S´liwin´ska-Mosson´ et al.: Metallothionein and p53 protein in SCA
Figs. 1–8. Immunohistochemical localization of MT and p53 in normal pancreas and tumors of the pancreas. Fig. 1. Positive staining for MT
in a few acinar cells of the normal pancreas (×210). Fig. 2. Negative staining for p53 in tissues of normal pancreas (×210). Figs. 3–4. Patient
no. 4: negative staining for MT and p53 in tissues of benign (SCA) tumor (×137, ×210). Figs. 5–6. Patient no. 3: moderate immunohisto-
chemical MT reaction limited to the lining epithelium of a neoplastic cyst and no reaction for p53 protein (×257; ×210). Figs. 7–8.
Malignant tumors of the pancreas: strong MT and p53 immunohistochemical reaction in the carcinoma cells (×210).
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The prognoses of the patients with positive expres-
sion of MT and p53 were significantly poorer than of
those with negative expressions of these parameters.
DISCUSSION
The tumor suppressor protein p53 is able to respond
to different cellular stresses, such as DNA damage,
hypoxia, oxidative stress, and oncogene activation.
Upon activation, p53 initiates a number of cellular activ-
ities that can ultimately culminate in G1 or G2 cell-cycle
arrest and DNA repair, apoptosis, or other cellular
changes (Schwartz and Rotter 1998). As a critical cellu-
lar mediator of the response to genotoxic damage, p53
has a direct role in maintaining genome integrity. Loss
of p53 activity has been associated with tumor progres-
sion and unfavorable prognosis (Symonds et al. 1994). It
was recently found that there is an association between
MT and p53 expression in lung and breast cell carcino-
mas (Fan and Cherian 2002; Joseph et al. 2001).
However, the mechanism of tumor MT and p53 expres-
sion is not fully understood. 
Metallothionein plays an important role in the
homeostasis of zinc, a metal important for tumor growth
and progression (Cherian 1994; Fan and Cherian 2002).
There are mechanisms whereby MT and p53 may inter-
act in the control of cell division. In vitro studies have
shown that exposure to a metal chelating agent induces
a reversible conformational change in wild-type p53 to
a mutant form. It was thought that the binding of zinc
ions to cysteinyl residues stabilizes the tertiary structure
of p53 (Hainaut and Milner 1993). MT also has a high
affinity to zinc ions and could thus act as an intracellu-
lar sequester of zinc. Ioachim et al. reported that cells
containing MT in quantities sufficient to reduce
intranuclear zinc ion levels and thus induce functional
inactivation of p53 would acquire growth advantages
and thus be able to proliferate and accumulate muta-
tional events (Ioachim et al. 1999). Furthermore, Zeng
et al. reported that mutation-induced MT overexpres-
sion may interfere with the function of DNA-binding
zinc finger transcription factors involved in controlling
the expressions of a wide range of genes regulating cell
proliferation and apoptosis, such as p53, and conferring
growth advantage on the mutated cells (Zeng et al.
1991).
Recent studies have demonstrated a negative rela-
tionship between MT expression and apoptosis
(Hadama et al. 2002). MT-null cells have been shown to
be more sensitive to apoptosis induced by anticancer
drugs than MT-expressing cells. Furthermore, the trans-
duction of an MT-antisense oligomer decreases bcl-2
expression and augments apoptosis (Kondo et al. 1997).
These findings suggest that MT itself acts as an anti-
-apoptotic molecule and also upregulates other anti-
-apoptotic molecules. The overexpression of MT genes
and reduction in apoptotic cells have been found to be
associated in various human tumors (Hadama et al.
2002). A significant positive correlation between MT
expression and poor clinical outcome has been found in
breast carcinomas, colorectal carcinomas, and malig-
nant melanomas (Fan and Cherian 2002; Ioachim et al.
1999; Schmid et al. 1993; Zelger et al. 1993).
Ohshio et al. showed that positive staining for MT in
pancreatic carcinomas was related to the incidence of
metastasis, worse histological grading of the tumors, and
poor prognosis (Ohshio et al. 1996). These results are
compatible with our study (Fig. 7). MT staining was fre-
quently positive not only in metastatic regions, but also
in samples obtained from primary pancreatic regions.
These results suggest that MT-positive pancreatic can-
cers acquire an enhanced ability to produce MT as their
malignant potential increases (Milnerowicz et al. 2006;
Ohshio et al. 1996). In our study, MT staining was gen-
erally observed in the cytoplasm, but more than half of
the MT-positive cases of pancreatic carcinomas showed
nuclear as well as cytoplasmic staining. It is now known
that the subcellular localization of MT is regulated in
cells undergoing proliferation, developmental progres-
sion, and tumorigenesis (Cherian and Apostolova 2000).
Cancer cells with nuclear MT may be more aggressive
than cells with only cytoplasmic staining for MT because
patients with nuclear staining survived for only two
months. Our study shows that positive staining for MT
in pancreatic carcinomas is related to the p53 expression
of the tumor cells and to poorer prognosis.
The localization and role of MT in serous cystade-
noma of the pancreas have not yet been not reported in
the literature. In our study a weak MT expression was
observed in SCA epithelial cells. The MT expression in
SCA was similar to that in cells of normal pancreas. In
this study we also employed immunohistochemical tech-
niques to detect the alteration of p53 in SCAs. It has
been shown that in various neoplasms and human pan-
creatic carcinoma cells lines, high-level expression of
immunohistochemically detectable p53 correlates with
p53 gene mutation (Bartsch et al. 1998; Satoh et al.
1996). In carcinoma lesions, the occurrence of K-ras and
p53 alterations was as high (90 and 70%, respectively) as
that shown in pancreatic carcinoma (Bartsch et al. 1998;
Satoh et al. 1996). Recent genetic studies demonstrated
that serous cystoadenomas are benign tumors of the
pancreas. K-ras mutations have not been detected in
serous cystadenoma of the pancreas (Bartsch et al. 1998;
Gerdes et al. 2003; Ishikawa et al. 1998). The immuno-
histochemical localization of p53 was negative in all
SCA cases. These results correlate with good prognosis
and benign tumor lesions. The immunohistochemical
investigation of the presence of mutated p53 gene
showed its lack in SCA cells, which demonstrates cor-
rect function of the suppressor p53 gene in pancreatic
SCA. The weak MT expression in SCA confirms the
lack of a potentially invasive, local character of the neo-
plastic lesion; MT may therefore be considered a pan-
creatic neoplastic marker. Its degree of expression will
indicate the type of tumor change. However, further
studies are necessary to prove this claim. 
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In conclusion, in this study MT and p53 expression
were observed in the majority of pancreatic carcinomas
and were not observed in benign tumors. 
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